NCT01852708View on ClinicalTrials.gov

Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood

CompletedOBSERVATIONAL
Enrollment

1,059

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Trisomy 21Trisomy 18Trisomy 13Sex Chromosome AbnormalitiesMicrodeletion Syndromes
Trial Locations (9)

10032

Columbia University, New York

10050

GenePhile Biosciences, Taipei

19104

The Children's Hospital of Philadelphia, Philadelphia

20010

Washington Women's Wellness Center, Washington D.C.

77054

Dr. Meltzer Clinic, Houston

91776

MFM Group of Southern CA, San Gabriel

94070

Natera, Inc., San Carlos

08901

Saint Peter's University Hospital, New Brunswick

08035

Hospital Materno Infantil Vall d'Hebron, Barcelona

Sponsors

Lead Sponsor

Natera, Inc.
All Listed Sponsors
lead

Natera, Inc.

INDUSTRY

NCT01852708 - Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood | Biotech Hunter | Biotech Hunter